Corporate Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heat-sensitive liposomal nanoparticle licensed from Duke University.

In June 2014 Celsion acquired EGEN, Inc., a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult-to-treat diseases. The acquisition established Celsion as a fully integrated oncology company, with programs on the leading edge of cancer research and with end-to-end R&D talent and competencies ranging from drug development to commercialization.

Today, Celsion has assets in directed chemotherapies, immunotherapies, and DNA- and RNA-based therapies. With clinical programs in Phases I, II, and III, and with an extensive pipeline of pre-clinical product candidates, Celsion is well positioned to deliver innovative new therapies to address areas of pressing unmet medical need in oncology.